Drs. Block and Strome founded Gliknik as part of their deep commitment to improving human health.
David S. Block – President and CEO
David founded Gliknik in 2007 after 17 years in industry, 12 of which were in a series of commercial positions at DuPont Merck and DuPont Pharmaceuticals including sales management, licensing, R&D portfolio planning, market development, and product launch. He was the EVP of International Operations at the time of the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb. From 2002 to 2004, David was the Chief Operating Officer of Celera Genomics. Prior to founding Gliknik, he formed and ran a venture-backed CNS start-up. David received his M.D. and M.B.A. at the University of Pennsylvania and was board-certified in Internal Medicine before entering the biopharmaceutical industry.
Scott E. Strome, M.D. – Founding Scientist
Dr. Strome, Gliknik’s scientific founder, is Professor and Chairman of the Dept. of Otorhinolaryngology-Head & Neck Surgery (OTO-HNS) at the University of Maryland School of Medicine with a secondary appointment in Immunology and Microbiology. Previously, he was an Associate Professor of OTO-HNS at the Mayo Clinic College of Medicine where he worked with and patented the use of anti-PD-L1 for the treatment of cancer with Lieping Chen, M.D., Ph.D. He received his M.D. from the Harvard Medical School and completed his residency in OTO-HNS at the University of Michigan. He currently runs a translational immunology laboratory dedicated to the development of active and passive immunologic approaches for the treatment of malignant and autoimmune diseases.